ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
4.860
-0.370 (-7.07%)
Jul 24, 2026, 4:00 PM EDT - Market closed

ENDRA Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
4.373.917.635.526.66.02
Research & Development
2.11.853.1956.555.48
Total Operating Expenses
6.475.7610.8210.5213.1611.5
Operating Income
-6.47-5.76-10.82-10.52-13.16-11.5
Other Non-Operating Income (Expense)
0.14-1.26-0.690.46-0.02-0.31
Total Non-Operating Income (Expense)
0.14-1.26-0.690.46-0.02-0.31
Pretax Income
-7.3-7.03-11.51-10.06-13.18-11.23
Net Income
-7.3-7.03-11.51-10.06-13.18-11.23
Net Income Attributable to Preferred Dividends
-----0.12
Net Income to Common
-7.3-7.03-11.51-10.06-13.18-11.35
Net Income Growth
------
Shares Outstanding (Basic)
110---
Shares Outstanding (Diluted)
110---
Shares Change
178.63%289.41%----
EPS (Basic)
-8.15-8.93-56.94---
EPS (Diluted)
-8.15-8.93-56.94---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-5.01-5.2-7.42-9.58-12.97-11.17
Free Cash Flow Growth
------
Free Cash Flow Per Share
-5.29-6.61-36.70---
EBITDA
-6.43-5.72-10.77-10.4-13.06-11.38
EBIT
-6.47-5.76-10.82-10.52-13.16-11.5
SEC Filings: 10-K · 10-Q